Atlas Trials

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Clinical trial NCT05885412 · RECRUITING

Trial details

NCT number
NCT05885412
Sponsor
Rocket Pharmaceuticals Inc.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Start date
2023-08-29
Primary completion
2028-09-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.